NCT00762632已完成1 期
An Open-label Phase I/II (Proof of Concept) Trial of an Combination of Nilotinib (AMN 107) and RAD001 in Patients With Acute Myeloid Leukemia
Technical University of Munich2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2007年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- To determine the rate of hematological response in adult patients with c-kit + AML. state the primary objective of the study
研究概览
简要总结
This is a nonrandomized, open-label study to evaluate the efficacy and safety of combination treatment of Nilotinib and RAD001 in the treatment of c-kit + AML. Patients refractory to standard chemotherapy or not eligible to standard chemotherapy can be included. Patients will be treated with 400 mg Nilotinib bid (total daily dose 800 mg). RAD001 will be added after a treatment duration of 1 week in a dosage of 2,5 mg/day. Treatment duration will be 25 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with:
- •De novo AML or secondary AML from MDS who are not candidates for myelosuppressive chemotherapy, or
- •De novo AML or secondary AML from MDS who have relapsed disease or are refractory to standard therapy
- •Patients at least 18 years or older
- •Patients with WHO performance status of 0 to 2 with a life expectancy under treatment of at least 3 months
- •Patients must have recovered from prior cytotoxic chemotherapy; treatment with Hydroxyurea or Ara-C is allowed until 24 hours to first administration of study drug.
- •Patients must have a serum creatinine of <= 1.5 x ULN, SGOT/SGPT <= 3 x ULN and total bilirubin <= 2.0 x ULN
- •Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
- •Written informed consent obtained according to local guidelines
排除标准
- •Patients with AML FAB M
- •Patients with an expected doubling of the peripheral blast within one week.
- •Patients who had prior allogeneic, syngeneic, or autologous bone marrow transplant or stem cell transplant less than 2 months previously.
- •Impaired cardiac function, including any one of the following:
- •LVEF < 45% or below the institutional lower limit of the normal range (whichever is higher) as determined by MUGA scan or echocardiogram
- •Complete left bundle branch block
- •Use of a cardiac pacemaker
- •ST depression of > 1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads
- •Congenital long QT syndrome dose levels of 400 to 1200 mg QD. Many of the common adverse events reported in the imatinib Phase II leukemia (STI0106, STI0110) studies were also reported in the nilotinib Phase I study, although a notably lower frequency of peripheral edema was identified in the nilotinib study.
- •History of or presence of significant ventricular or atrial tachyarrhythmias
- •Clinically significant resting bradycardia (< 50 beats per minute)
- •QTc > 450 msec on screening ECG (using the QTcF formula)
- •QT prolonging concomitant medication
- •Right bundle branch block plus left anterior hemiblock, bifascicular block
- •Myocardial infarction within 12 months prior to starting Nilotinib
- •Unstable angina diagnosed or treated during the past 12 months
- •Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
- •Female patients who are pregnant or breast feeding, or adults of childbearing age not employing an effective method of birth control.
- •Concurrent severe and/or uncontrolled medical or psychiatric condition which may interfere with the completion of the study.
- •Patients who had more than 2 prior regimens for their current relapsed or current primary refractory disease
- •Patients with uncontrolled active infection.
- •Patient with any pulmonary infiltrate on the baseline chest X-ray known to be new in the previous 4 weeks. Prior treatment with any investigational drug within the preceding 4 weeks
- •Chronic treatment with systemic steroids or another immunosuppressive agent
- •Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
- •Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.
- •Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias active ischemic heart disease, myocardial infarction within six months, chronic liver or renal disease, active upper GI tract ulceration)
- •A known history of HIV seropositivity
- •Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
- •Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumarin)
- •Hypokalemia
- •Women who are pregnant or breast feeding, or women able to conceive and unwilling to practice an highly effective method of birth control.
- •Patients who have received prior treatment with an mTor inhibitor.
- •History of noncompliance to medical regimens
- •Patients unwilling to or unable to comply with the protocol
结局指标
主要结局
To determine the rate of hematological response in adult patients with c-kit + AML. state the primary objective of the study
时间窗: four years
次要结局
- To determine the duration of hematological response. To evaluate overall survival. To evaluate the safety profile of a combination treatment of Nilotinib and RAD001. • To evaluate improvement of symptomatic parameters. • To assess mTor, cKit a(four years)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19COVID19NCT04551768Bausch Health Americas, Inc.51
撤回
1 期
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2COVID19NCT04356677Bausch Health Americas, Inc.
Unknown
2 期
Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal CancerMetastatic Colorectal CancerNCT01249521Austin Health40
已完成
1 期
Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and YouthHIV InfectionsNCT04301154Henry M. Jackson Foundation for the Advancement of Military Medicine25
已完成
1 期
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT01558167German CLL Study Group22